BiotechTube
NeoPhore

NeoPhore

Cambridge, United Kingdom· Est.
neophore.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $27.2M

Overview

NeoPhore is pioneering a novel immuno-oncology approach by pharmacologically inducing a transient state of MMR deficiency in tumors to unlock immunotherapy responses. Founded on seminal academic research, the company has developed a platform to discover small molecule MMR inhibitors and has validated its hypothesis in preclinical models. Backed by a strong syndicate of life science investors, including Bristol Myers Squibb, NeoPhore is advancing towards clinical testing with the goal of significantly broadening patient access to transformative cancer immunotherapies.

Oncology

Technology Platform

Platform for discovering first-in-class small molecule inhibitors of the DNA Mismatch Repair (MMR) pathway, aiming to transiently induce an MMR-deficient state in tumors to sensitize them to immunotherapy.

Funding History

2
Total raised:$27.2M
Series A$24M
Seed$3.2M

Opportunities

The primary opportunity is to dramatically expand the addressable patient population for immune checkpoint inhibitors by converting MMR-proficient tumors, which represent the vast majority of cancers, into immunotherapy-responsive states.
This could unlock multi-billion dollar markets in major solid tumors like colorectal and endometrial cancer.
Furthermore, strategic validation from Bristol Myers Squibb provides a pathway for potential future co-development and commercialization partnerships.

Risk Factors

Key risks include the unproven clinical efficacy and potential safety concerns of transiently inhibiting a core DNA repair pathway, which may lead to genotoxicity or secondary malignancies.
As a preclinical company, NeoPhore also faces significant development execution risk and will require substantial additional capital to advance through clinical trials.

Competitive Landscape

NeoPhore's approach is novel, with no approved pharmacological MMR inhibitors on the market. Competition exists from other strategies to overcome immunotherapy resistance (e.g., targeting other immunosuppressive pathways, novel cytokine therapies, and cancer vaccines) and from diagnostics identifying patients with innate MMR deficiency. The company's first-in-pathway position is a key differentiator, but it may face future competition from larger biopharma entrants if the concept is clinically validated.

More companies in Small Molecule Drugs →More companies in United Kingdom →